The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Subscribe to Continue Reading
Uh oh–you've read all five of your free articles for this month.
Insider Online Only
$19.95/yr US PRICE
The Mystery of Knotted Proteins
Biologists are getting closer to figuring out why nature ties knots in some molecules, which could lead to better drug discovery.
Solving the Lack of Diversity in Genomic Research
An overwhelming majority of the data collected is from people of European ancestry. But researchers are trying to change that.
Pokemon Go Increased U.S. Activity Levels by 144 Billion Steps in Just 30 Days
The latest gaming craze increases activity levels for players, regardless of their age, sex, or weight.